Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12, ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...

Given these findings, a diagnosis of HAC of the colon with metastasis to a mesenteric lymph node was made. We present the case of a young woman with hepatoid adenocarcinoma (HAC) of the colon, which ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

The American people have consistently supported life-saving cancer research. Now the nation’s bedrock source of public funding for biomedical research is under attack.

Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

University of California on What Cuts to National Institutes of Health (NIH) Funding Mean for Cancer Patients and Their ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.